Skip to main content

WVE

Stock
Health Care
Biotechnology

Performance overview

WVE Price
Price Chart

Forward-looking statistics

Beta
1.60
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.

Company info

SectorHealth Care
IndustryBiotechnology
Employees283
Market cap$711.5M

Fundamentals

Enterprise value$790.3M
Revenue$104.9M
Revenue per employee
Profit margin-107.04%
Debt to equity13.13

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.75
Dividend per share
Revenue per share$0.72
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$9M
Put-call ratio

Macro factor sensitivity

Growth-8.3
Credit+10.1
Liquidity+8.3
Inflation-14.6
Commodities-5.9
Interest Rates-0.5

Valuation

Dividend yield0.00%
PEG Ratio-7.09
Price to sales10.30
P/E Ratio-7.09
Enterprise Value to Revenue7.53
Price to book6.23

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.

Zacks Investment Research (May 8, 2025)
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Wave Life Sciences Ltd. WVE released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Benzinga (March 26, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free